Alafair’s VersaWrap Nerve Protector is indicated for the management of peripheral nerve injuries, in which there has been no substantial loss of nerve tissue. Credit: Nephron.

US-based medical device company Alafair Biosciences has received 510(k) clearance from the US Food and Drug Administration (FDA) for its VersaWrap Nerve Protector.

VersaWrap Nerve Protector, which similar to the company’s VersaWrap Tendon Protector indicated for tendon, is an ultra-thin, sutureless, bioresorbable hydrogel implant.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

It is indicated for the management of peripheral nerve injuries, in which there has been no substantial loss of nerve tissue.

The device is designed to create a permeable, gelatinous layer on or around the peripheral nerve to provide a non-constricting interface between nerve and surrounding tissues during healing.

Furthermore, VersaWrap Nerve Protector enables better clinical outcome in patients when scarring is a concern.

Alafair CEO Greg Brophy said: “We are pleased to have received 510(k) clearance for VersaWrap and believe that we will see rapid surgeon adoption given the unique characteristics of our product.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

“Our patented hydrogel technology has diverse applications in the medical device and regenerative medicine segments, and the extension of our product portfolio to include peripheral nerve procedures is a substantial milestone for our organisation.”

Alafair plans to approach the US FDA with additional 510(k) filings to expand the clinical applications for the use of its hydrogel technology.

The company has a portfolio of 25 issued and ten pending patents, covering a range of clinical applications based on its patented hydrogel technology.

Alafair focuses on building its product pipeline based on proprietary technology. The company distributes its products through a network of independent distributors across the US.